Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages

Bradley K. Ackerson,Katia J. Bruxvoort,Lei Qian,Lina S. Sy,Sijia Qiu,Julia E. Tubert,Gina S. Lee,Jennifer H. Ku,Ana Florea,Yi Luo,Radha Bathala,Julie Stern,Soon K. Choi,Harpreet S. Takhar,Michael Aragones,Morgan A. Marks,Evan J. Anderson,Cindy Ke Zhou,Tianyu Sun,Carla A. Talarico,Hung Fu Tseng,Bradley K. AckersonKatia J. BruxvoortLei QianLina S. SySijia QiuJulia E. TubertGina S. LeeJennifer H. KuAna FloreaYi LuoRadha BathalaJulie SternSoon K. ChoiHarpreet S. TakharMichael AragonesMorgan A. MarksEvan J. AndersonCindy Ke ZhouTianyu SunCarla A. TalaricoHung Fu Tsenga Department of Research and Evaluation,Kaiser Permanente Southern California,Pasadena,CA,USAb Department of Epidemiology,University of Alabama at Birmingham,Birmingham,AL,USAc Infectious Disease,Epidemiology,Moderna Inc,Cambridge,MA,USAd Epidemiology,AstraZeneca,Gaithersburg,MD,USAe Department of Health Systems Science,Kaiser Permanente Bernard J. Tyson School of Medicine,Pasadena,CA,USA

DOI: https://doi.org/10.1080/21645515.2024.2335052

2024-04-06

Human Vaccines & Immunotherapeutics

Abstract:Emerging SARS-CoV-2 sublineages continue to cause serious COVID-19 disease, but most individuals have not received any COVID-19 vaccine for >1 year. Assessment of long-term effectiveness of bivalent COVID-19 vaccines against circulating sublineages is important to inform the potential need for vaccination with updated vaccines. In this test-negative study at Kaiser Permanente Southern California, sequencing-confirmed BA.4/BA.5- or XBB-related SARS-CoV-2-positive cases (September 1, 2022 to June 30, 2023), were matched 1:3 to SARS-CoV-2-negative controls. We assessed mRNA-1273 bivalent relative (rVE) and absolute vaccine effectiveness (VE) compared to ≥2 or 0 doses of original monovalent vaccine, respectively. The rVE analysis included 20,966 cases and 62,898 controls. rVE (95%CI) against BA.4/BA.5 at 14–60 days and 121–180 days was 52.7% (46.9–57.8%) and 35.5% (−2.8–59.5%) for infection, and 59.3% (49.7–67.0%) and 33.2% (−28.2–68.0%) for Emergency Department/Urgent Care (ED/UC) encounters. For BA.4/BA.5-related hospitalizations, rVE was 71.3% (44.9–85.1%) and 52.0% (−1.2–77.3%) at 14–60 days and 61–120 days, respectively. rVE against XBB at 14–60 days and 121–180 days was 48.8% (33.4–60.7%) and −3.9% (−18.1–11.3%) for infection, 70.7% (52.4–82.0%) and 15.7% (−6.0–33.2%) for ED/UC encounters, and 87.9% (43.8–97.4%) and 57.1% (17.0–77.8%) for hospitalization. VE and subgroup analyses (age, immunocompromised status, previous SARS-CoV-2 infection) results were similar to rVE analyses. rVE of mRNA-1273 bivalent vaccine against BA.4/BA.5 and XBB infections, ED/UC encounters, and hospitalizations waned over time. Periodic revaccination with vaccines targeting emerging variants may be important in reducing COVID-19 morbidity and mortality.

immunology,biotechnology & applied microbiology